Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping

Oncologist. 2022 May 6;27(5):e420-e421. doi: 10.1093/oncolo/oyac057.


In response to the recently published article by Sharma et al, this letter to the editor presents data about the concordance of blood and normal tissue-based evaluation of DPYD genotyping that suggests that pharmacogenetic screening could be contextual to tumor molecular profiling.

Publication types

  • Letter
  • Comment

MeSH terms

  • Capecitabine
  • Dihydrouracil Dehydrogenase (NADP)* / genetics
  • Fluorouracil*
  • Genotype
  • Humans


  • Capecitabine
  • Dihydrouracil Dehydrogenase (NADP)
  • Fluorouracil